CRVS Stock Summary and Trading Ideas (Corvus Pharmaceuticals | NASDAQ:CRVS)

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's main product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.

Corvus Pharmaceuticals trades on the NASDAQ stock market under the symbol CRVS.

As of April 22, 2024, CRVS stock price climbed to $1.44 with 126,918 million shares trading.

CRVS has a beta of 1.25, meaning it tends to be more sensitive to market movements. CRVS has a correlation of 0.02 to the broad based SPY ETF.

CRVS has a market cap of $70.62 million. This is considered a Micro Cap stock.

In the last 3 years, CRVS stock traded as high as $9.54 and as low as $.61.

The top ETF exchange traded funds that CRVS belongs to (by Net Assets): VTI, VXF, IWC, AVSC, DFAC.

CRVS has outperformed the market in the last year with a return of +32.1%, while the SPY ETF gained +22.3%. However, in the most recent history, CRVS shares have underperformed the stock market with its stock returning -27.6% in the last 3 month period and -17.7% for the last 2 week period, while SPY has returned +3.9% and -3.6%, respectively.

CRVS support price is $1.32 and resistance is $1.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRVS stock will trade within this expected range on the day.